Zelda Therapeutics Limited (ZLDAF)

0.4800 0.0000 (0.00%) At close: 01:07PM EDT

Zelda Therapeutics Limited

101 St George's Terrace
Level 3
Perth, WA 6000
Australia
61 8 6558 0886
https://zeliratx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Osagie O. Imasogie Esq.	Founder & Chairman	94.62k	N/A	1962
Dr. Oludare Odumosu	MD, Global CEO & Director	314.58k	N/A	N/A
Mr. Greg Blake	Executive Director	166.41k	N/A	N/A
Mr. Timothy Ryan Slate	Company Secretary & Non-Executive Director	23.66k	N/A	N/A
Mr. Rahul Ganesan	Vice President of Finance & Accounting	N/A	N/A	N/A
Dr. Patty Washer	Clinical Trial Consultant	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. It also provides over the counter products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.

Corporate governance

Zelda Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.